Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Company reports Q4 revenue of $132.7M, discusses remarketing of Tysabri
February 27th, 2006
Elan Corp., plc, announced its fourth-quarter and full-year 2005 financial results and provided guidance for its financial outlook for 2006. Total product revenue for the fourth quarter of 2005 of $132.7 million increased 30% from $102.3 million recorded in the same quarter of 2004. The increase is primarily due to higher revenue from marketed products and higher manufacturing revenue and royalties. Total product revenue for the full-year 2005 was $458.1 million, compared to $404.4 million for the same period of 2004, an increase of 13%. The increase in product revenue from the core business of 34% for the full-year 2005 significantly exceeded the loss of revenues from...
Source: Pharma Business Week (2006-02-27)
|
